DiaMedica Therapeutics Inc.
DMACAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 7, 2024 | Truist Financial | Bill Chappell | $10.00(+126%) | $4.42 | Benzinga |
| Oct 7, 2024 | H.C. Wainwright | Matthew Caufield | $7.00(+61%) | $4.36 | TheFly |
| Mar 21, 2024 | Craig-Hallum | Alex Nowak | $8.00(+197%) | $2.69 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Aug 11, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 15, 2025 |
| Lake Street | maintain | Buy | Jul 18, 2025 |
| Craig-Hallum | maintain | Buy | Jul 18, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jul 18, 2025 |
| HC Wainwright & Co. | maintain | Buy | May 29, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 19, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 10, 2024 |
| Oppenheimer | maintain | Outperform | Aug 16, 2024 |
| Oppenheimer | maintain | Outperform | Mar 21, 2024 |
| Craig-Hallum | maintain | Buy | Mar 21, 2024 |
| Oppenheimer | upgrade | Perform →Outperform | Jun 22, 2023 |
| Lake Street | maintain | Buy | Jul 7, 2022 |
| Oppenheimer | downgrade | Outperform →Perform | Jul 7, 2022 |
| Craig-Hallum | maintain | Buy | Jul 7, 2022 |
| Roth Capital | maintain | Buy | Jun 30, 2021 |
| Oppenheimer | maintain | Outperform | Apr 9, 2021 |
| Oppenheimer | maintain | Outperform | Apr 8, 2021 |
| Roth Capital | maintain | Buy | Feb 17, 2021 |
| Maxim Group | maintain | Buy | Jul 8, 2020 |
| Craig-Hallum | maintain | Buy | May 15, 2020 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.20| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 10, 2026 | $-0.19 | $-0.20 | — | $13.5M |
| May 6, 2026 | $-0.19 | $-0.17 | — | $13.5M |
| Mar 30, 2026 | $-0.17 | $-0.17 | — | — |
| Nov 12, 2025 | $-0.17 | $-0.15 | — | — |
| Aug 12, 2025 | $-0.18 | $-0.18 | — | — |
| May 13, 2025 | $-0.18 | $-0.18 | — | — |
| Mar 17, 2025 | $-0.18 | $-0.17 | — | — |
| Nov 13, 2024 | $-0.15 | $-0.15 | — | — |
News
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that its third quarter 2026 financial results will be released after the markets close on Thursday, November 12th. DiaMedica will host a live conference call on Friday, November 13th at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth res
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that the 200th patient has been enrolled in its pivotal Phase 2/3 ReMEDy2 trial of DM199 (rinvecalinase alfa) in participants with acute ischemic stroke (AIS), reaching the prespecified enrollment threshold for the trial's planned interim analysis. Under th.
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction (FGR) and acute ischemic stroke, today announced that its virtual key opinion leader (KOL) event, previously scheduled for October 23, 2026, will now be held on Tuesday, November 24, 2026, at 8:00am Eastern Time. The new date will allow the Company to expand the presentation to include preliminary,.
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that it will host a virtual key opinion leader (KOL) event on October 23, 2026 at 8:00am Eastern Time to discuss fetal growth restriction (FGR), the therapeutic rationale for evaluating DM199 (rinvecalinase alfa) as a potential treatment for FGR and prelimi.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth res
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that company management will participate in four upcoming investment bank conferences in New York. Details Citi Biopharma Back to School Summit September 9-10, 2026 Cantor Global Healthcare Conference September 9-11, 2026 Fireside Chat with Rick Pauls (CEO).
The average of price targets set by Wall Street analysts indicates a potential upside of 130% in DiaMedica Therapeutics (DMAC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
DiaMedica Therapeutics (DMAC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
DiaMedica Therapeutics Inc. (DMAC) Q2 2026 Earnings Call Transcript
DiaMedica Therapeutics NASDAQ: DMAC said its second-quarter progress centered on advancing DM199 across early-onset fetal growth restriction (FGR), preeclampsia and acute ischemic stroke, while the company reported a cash runway it expects to extend through 2027.
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today provided a business update and reported financial results for the second quarter ended June 30, 2026. Management will host a conference call Tuesday, August 11, 2026, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and second quarter 202.